LBF20207PG26: Difference between revisions

No edit summary
No edit summary
 
(14 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Lipid/Header}}
{{Hierarchy|{{PAGENAME}}}}
{{Hierarchy|{{PAGENAME}}}}
{{Lipid/Header}}


{{Metabolite
{{Metabolite
|LipidBank=XPR1511
|LipidBank=XPR1511
|LipidMaps=LMFA03010026
|LipidMaps=LMFA03010026
|SysName=7- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3-oxo-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid
|SysName=7- [ (3R,5S) -Dihydroxy-2R - (3-oxo-trans-1-octenyl)- cyclopentan-1R -yl] -cis-5-heptenoic acid
|Common Name=&&15-KETOPROSTAGLANDIN F_2alpha&&7- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3-oxo-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid&&
|Common Name=&&15-keto Prostaglandin F_2 alpha&&7- [ (3R,5S) -Dihydroxy-2R - (3-oxo-1(E)-octenyl)- cyclopentan-1R -yl ] -5-(Z)-heptenoic acid&&
|Source=15-Keto-prostaglandin F2 alpha  is the oxidized product of prostaglandin F2 alpha  by 15-hydroxyprostaglandin dehydrogenase, which is present in lung, kidney, placenta and other tissues and catalyzes the NAD- or NADP-dependent dehydrogenation of 15-dydroxyl group [[Reference:Hansen_HS:,Prostaglandins,1976,12,647|{{RelationTable/GetFirstAuthor|Reference:Hansen_HS:,Prostaglandins,1976,12,647}}]].
|Chemical Synthesis=
|Metabolism=15-Keto-prostaglandin F2 alpha  is further metabolized by its  Delta 13-reduction,  beta -oxidation and  omega  oxidation. The ultimate metabolite is 5 alpha ,7 alpha -dihydroxy-11-keto-tetranorprosta-1,16-dioic acid, and excreted in urine [[Reference:Granstrom_E:Samuelsson_B:,J. Biol. Chem.,1971,246,5254|{{RelationTable/GetFirstAuthor|Reference:Granstrom_E:Samuelsson_B:,J. Biol. Chem.,1971,246,5254}}]].
|Symbol=15-KETO-PGF2α
|Biological Activity=It is well known that the biological activities of various prostaglandins are reduced upon their dehydrogenation at carbon-15 by the catalysis of 15-hydroxyprostaglandin dehydrogenase [[Reference:Anggard_E:,Acta Physiol. Scand.,1966,66,509|{{RelationTable/GetFirstAuthor|Reference:Anggard_E:,Acta Physiol. Scand.,1966,66,509}}]].
|Genetic Information=cDNA for placental 15-hydroxyprostaglandin dehydrogenase was cloned [[Reference:Ensor_CM:Tai_HH:,J. Lipid Mediat. Cell Signal.,1995,12,313|{{RelationTable/GetFirstAuthor|Reference:Ensor_CM:Tai_HH:,J. Lipid Mediat. Cell Signal.,1995,12,313}}]].
}}
}}


{{Lipid/Footer}}
{{Lipid/Footer}}

Latest revision as of 08:30, 21 October 2010

LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



15-keto Prostaglandin F2α
LBF20207PG26.png
Structural Information
7- [ (3R,5S) -Dihydroxy-2R - (3-oxo-trans-1-octenyl)- cyclopentan-1R -yl] -cis-5-heptenoic acid
  • 15-keto Prostaglandin F2α
  • 7- [ (3R,5S) -Dihydroxy-2R - (3-oxo-1(E)-octenyl)- cyclopentan-1R -yl ] -5-(Z)-heptenoic acid
15-KETO-PGF2α
Formula C20H32O5
Exact Mass 352.224974134
Average Mass 352.46508
SMILES C(CCC(=O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@@H](C[C@@H]1O)O)CC
Physicochemical Information
15-Keto-prostaglandin F2 alpha is the oxidized product of prostaglandin F2 alpha by 15-hydroxyprostaglandin dehydrogenase, which is present in lung, kidney, placenta and other tissues and catalyzes the NAD- or NADP-dependent dehydrogenation of 15-dydroxyl group Hansen_HS .
15-Keto-prostaglandin F2 alpha is further metabolized by its Delta 13-reduction, beta -oxidation and omega oxidation. The ultimate metabolite is 5 alpha ,7 alpha -dihydroxy-11-keto-tetranorprosta-1,16-dioic acid, and excreted in urine Granstrom_E et al..
It is well known that the biological activities of various prostaglandins are reduced upon their dehydrogenation at carbon-15 by the catalysis of 15-hydroxyprostaglandin dehydrogenase Anggard_E .
cDNA for placental 15-hydroxyprostaglandin dehydrogenase was cloned Ensor_CM et al..
Spectral Information
Mass Spectra
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20207PG26 See above. Anggard_E 1966
n.a. LBF20207PG26 See above. Ensor_CM et al. 1995
n.a. LBF20207PG26 See above. Granstrom_E et al. 1971
n.a. LBF20207PG26 See above. Hansen_HS 1976